An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.

开始日期2001-07-01

申办/合作机构

Jonsson Comprehensive Cancer Center

NCT02118077

/ Completed临床3期

A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

开始日期2001-04-01

申办/合作机构

Cancer Advances, Inc.

NCT02118064

/ Completed临床2期

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

开始日期2001-03-01

申办/合作机构

Cancer Advances, Inc.

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的专利（医药）

登录后查看更多信息

2,697

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的文献（医药）

2025-05-01·JOURNAL OF ETHNOPHARMACOLOGY

Genus Senecio in China: A review on its traditional uses, phytochemistry, pharmacology, and toxicity

Review

作者: Cheng, Shiji ; Wan, Li ; Lu, Yang ; Wu, Mengyao ; Tao, Chengtian ; Wu, Yuyang ; Zhang, Jiaxiong ; Li, Ruiyu

ETHNOPHARMACOLOGICAL RELEVANCE:

The genus Senecio comprises approximately 1500 species worldwide, with over 60 species distributed throughout China. These plants have been widely used in traditional Chinese medicine to treat various conditions including inflammation, eye diseases, vaginal trichomoniasis, and acute urinary tract infections.

AIM OF THE REVIEW:

This review aims to provide a comprehensive analysis of the geographical distribution, traditional uses, phytochemical composition, pharmacological activities, and toxicology of medicinally important Senecio species in China. Furthermore, we critically evaluate future research directions to provide valuable insights for subsequent research and development of this genus.

MATERIALS AND METHODS:

We collected and analyzed relevant literature from 1963 to 2023 using multiple databases including PubMed, Web of Science, ScienceDirect, Google Scholar, Elsevier, Sci Finder, CNKI, and Wan fang. We also examined doctoral and master's theses, the Chinese Pharmacopoeia (2020 edition), and various Materia Medica monographs. Plant nomenclature was verified using "The Plant List" (http://www.theplantlist.org).

RESULTS:

As traditional Chinese medicinal herbs, Senecio plants are commonly employed to treat acute inflammation, eye diseases, and pruritus. To date, 217 chemical constituents have been isolated and characterized from medicinal Senecio species, primarily including alkaloids, sesquiterpenes, flavonoids, phenolic acids, jacaranones, and volatile oils, along with minor amounts of lignans and steroids. Among these compounds, pyrrolizidine alkaloids (PAs) and furoeremophilanes represent the characteristic chemical constituents of the genus. Extensive studies have demonstrated that extracts and isolated compounds from Senecio plants exhibit diverse pharmacological activities, including antibacterial, anti-inflammatory, antitumor, antiviral, antioxidant, hepatoprotective, and analgesic effects. However, Senecio species also demonstrate specific toxicity profiles, primarily manifesting as acute toxicity, hepatotoxicity, and reproductive toxicity, with PAs identified as the main toxic components.

CONCLUSIONS:

Phytochemical and pharmacological studies have established Senecio species as valuable medicinal plants with significant bioactive properties. However, research has focused primarily on a limited number of species, necessitating comprehensive investigation of other species to identify additional medicinal candidates. Additionally, given that Senecio species generally contain toxic unsaturated PAs, with variations in both types and concentrations among different species, studying their toxic components and content profiles remains a priority for future research.

2025-05-01·JOURNAL OF CHROMATOGRAPHY A

Enhancing pyrrolizidine alkaloid separation and detection: LC-MS/MS method development and integration of ion mobility spectrometry into the LC-HRMS workflow

Article

作者: Dall'Asta, Chiara ; Carbonell-Rozas, Laura ; Foddy, Henry ; Dreolin, Nicola

Pyrrolizidine alkaloids (PAs) are plant toxins occurring in different foodstuffs, including teas, herbal infusions and species. Additionally, PAs may be transferred to honey and pollen when honeybees come into contact with contaminated plants. Due to their adverse effect, PAs occurrence in food must be controlled to ensure public health. Nevertheless, the presence of numeours PA epimers complicates their chromatographic separation and detection. In this regard, a method using liquid chromatography coupled with tandem mass spectrosmetry (LC-MS/MS) has been developed allowing the separation of 31 out of the 35 regulated PAs, which was sucessfully validated in different food matrices such as herbal infusions, spices and honey. Afterwards, travelling wave ion mobility spectrometry hyphenated with quadrupole time-of-flight mass spectrometry (TWIMS-QTOF) was evaluated to improve the analytical performance of PAs determination. Thus, collision cross section (CCS) values of PAs have been therefore obtained for the first time. The CCS library for PAs was also compared with predicted values by machine learning and with those meassured in real food matrices (bias <2 %). In addition, an in-house library was used in the suspect screening of PAs to complement the targeted analysis of the studied samples, all of which tested positive for several PAs.

2025-04-03·JOURNAL OF ADHESIVE DENTISTRY

Phosphoric Acid Modified With Polyphenol-Rich Plant Extracts: Bond Strength to Sound and Eroded Dentin.

Article

作者: Loguercio, Alessandro D ; Said Zayed, Mohamed Ahmed ; Niemeyer, Samira Helena ; Peutzfeldt, Anne ; Baumann, Tommy ; Carvalho, Thiago Saads

PURPOSE:

To modify phosphoric acid (PA) with polyphenol-rich plant extracts and verify their effect on immediate (24 h) and long-term (1 year) micro-shear bond strength (µSBS) of an adhesive system to sound and eroded dentin.

MATERIALS AND METHODS:

420 dentin specimens (360 for µSBS and 60 for characterization) were prepared and divided into two substrate-subgroups: sound (untreated) and eroded dentin (underwent 10 cycles of 1 h exposure to human saliva and 5 min immersion in citric acid). The specimens from each subgroup were randomly distributed into six groups, according to PA (n = 30/group): PA-EXP (experimental control), PA-GSE (PA-EXP + grape seed extract), PA-BLU (PA-EXP + blueberry extract), PA-CRA (PA-EXP + cranberry extract), PA-GRE (PA-EXP + green tea extract), PA-COM (commercial control). After etching with the respective PA (15 s), specimens were restored with adhesive and composite resin. Half of the specimens of each group were subjected to µSBS testing after 24 h and the other half after 1 year of storage (tap water, 37°C). Analyses were made with three-way ANOVA and post-hoc Tukey tests (α = 0.05).

RESULTS:

Higher µSBS was observed to sound dentin than to eroded dentin, regardless of the storage time, except for PA-BLU and PA-GSE after 1 year (p = 0.40 and p = 0.10, respectively). After 24 h, for both substrates, PA-COM presented statistically significantly lower µSBS than the other PAs. After 1 year, µSBS was significantly reduced for all groups except for the PA-COM (sound: p = 0.67; eroded: p = 0.13).

CONCLUSION:

Compared to the commercial PA, the modified PAs improved the immediate µSBS and gave similar long-term µSBS to sound as well to eroded dentin.

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的新闻（医药）

2023-02-28

·BioSpace

Cancer Advances, Inc. Announces Issuance of New U.S. Patent - February 28, 2023

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers. The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor. A related claim covers reduction in fibrosis associated with pancreatic cancer via the administration of this combination. “After more than six years of research, we are excited to have this patent issued. We have known that PAS can induce the development of antibodies to Gastrin, bringing Gastrin levels down and increasing survival times by 50% in GI clinical trials. With our research now demonstrating that PAS is able to alter the tumor microenvironment, it opens the door to many new opportunities to improve current treatment for GI cancer patients,” commented Lynda Sutton, President of Cancer Advances. The issued patent adds to the over one hundred granted global patents for PAS. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers. About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team with over one hundred and twenty years of combined experience in drug development and commercialization experience. About Polyclonal Antibody Stimulator (PAS) Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 human subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program. Contact Cancer Advances, Inc. E-mail: jwingen@canceradvances.com

疫苗免疫疗法

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB04914

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃癌	临床3期	美国	Cancer Advances, Inc.	2009-01-19
晚期胰腺腺癌	临床3期	-	Cancer Advances, Inc.	2001-02-01
胰腺癌	临床3期	-	Aphton Corp.	-
胃食管反流	临床2期	美国	Cancer Advances, Inc.	2009-01-20
食管癌	临床2期	-	Cancer Advances, Inc.	2000-08-01
胃食管交界处恶性肿瘤	临床2期	-	Cancer Advances, Inc.	2000-08-01
黄疸	临床2期	-	Cancer Advances, Inc.	1999-08-01
大肠腺癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01
转移性结直肠癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2006	临床3期	胰腺癌	-	Gemcitabine + G17DT	艱範壓衊餘選餘廠淵築(憲廠範獵顧壓選簾築醖) = 網鬱鬱鏇衊製壓衊鹽簾憲齋醖鬱製淵顧選壓壓 (襯遞築願鑰簾憲願窪夢 )	-	2006-06-20
				Gemcitabine alone (placebo)	艱範壓衊餘選餘廠淵築(憲廠範獵顧壓選簾築醖) = 艱壓膚糧積遞築艱淵鹽憲齋醖鬱製淵顧選壓壓 (襯遞築願鑰簾憲願窪夢 )
ASCO2004	N/A	不能切除性胰腺癌	154	G17DT	構積醖艱餘淵願窪構襯(構憲鑰選鹽憲膚廠壓膚) = 醖遞鑰網願製簾淵選遞鑰鹹餘蓋觸積蓋顧鬱選 (鹽蓋繭餘築壓選選齋遞 )	积极	2004-07-15
				Placebo	構積醖艱餘淵願窪構襯(構憲鑰選鹽憲膚廠壓膚) = 艱積獵衊積範膚觸鬱製鑰鹹餘蓋觸積蓋顧鬱選 (鹽蓋繭餘築壓選選齋遞 )